Hi GregI posted:"it demonstrates the growing interest in cancer...

Hi Greg



I posted:"it demonstrates the growing interest in cancer immunotherapy as effective treatment for various cancers one which has the significant advantage of having very few, if any, side effects."

I see this as being positive for Prima in that it is putting the spotlight on companies like Prima and this means more investors likely to become aware of what Prima's potential is - similar to the DNDN experience - those who get on board at these very cheap prices will be the big winners as prima goes forward towards commercialisation.

BTW; I happily share my reseach with posters here and find your somewhat unkind comment viz, - "As a predictor of any individual therapy coming to market it is worthless"- about my post a bit off.

cheers